Overweight Clinical Trial
— METOfficial title:
Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
Verified date | January 2018 |
Source | Anagnostou, Evdokia, M.D. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether metformin is safe and effective in the treatment of weight or weight gain in young people with Autism Spectrum Disorders (ASD) who are currently taking atypical antipsychotic medication.
Status | Completed |
Enrollment | 60 |
Est. completion date | October 2015 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility |
Inclusion Criteria: 1. Diagnosis of Autism Spectrum Disorder (autistic disorder, pervasive developmental disorder not otherwise specified), Asperger's disorder) based upon an Autism Diagnostic Observation Scale (ADOS) and Diagnostic and Statistical Manual (DSM-IV) interview. 2. Minimum of 1 month on a stable atypical antipsychotic dose with no plans to change the dose for the next 4 months. 3. A documented greater than/equal to 7% increase in BMI since starting atypical antipsychotic therapy(going back as far as prior 12 months); or, if BMI is greater or equal to 85th percentile corrected for age and sex, then a greater than 5% body weight increase per year (prorated at greater than 5% body weight increase if medicated for longer than a year). 4. Age 6 years to 17 years, 4 months. 5. Subjects and their parents (guardians) must be judged reliable for medication compliance and must agree to keep appointments for study visits and tests as outlined in the protocol. 6. Prior to the conduct of any study-specific procedures, the subject must provide assent to participate in the study (if developmentally appropriate), and their parents (guardians) must provide written informed consent. Exclusion Criteria: 1. History of intolerable adverse effects with metformin. 2. Prior history of an exposure to metformin of sufficient dose or duration to determine response status. 3. History of liver disease, renal impairment, congestive heart failure, pernicious anemia, any other condition increasing the risk for lactic acidosis, or any serious medical illness requiring treatment. 4. Use of cationic drugs excreted by the kidneys. 5. Planned surgery or procedure requiring contrast. 6. Pregnant at screening contact. 7. On other psychotropic concomitant medications for less than 2 months. 8. Treatment or planned treatment with concomitant medications with unacceptable interactions with metformin, including topiramate, levetiracetam, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, diuretics, or histamine H2 receptor antagonists. 9. Unable to tolerate blood work. 10. Current use of medication for target symptoms of appetite or weight loss. 11. Planned change of medication, medication dose, or behavioral treatment targeting weight loss during the study period. |
Country | Name | City | State |
---|---|---|---|
Canada | Holland Bloorview Kids Rehabilitation Hospital | Toronto | Ontario |
United States | Ohio State University/Nationwide Children's Hospital | Columbus | Ohio |
United States | Vanderbilt University | Nashville | Tennessee |
United States | University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Evdokia Anagnostou | Massachusetts General Hospital, Nationwide Children's Hospital, Ohio State University, University of Pittsburgh, Vanderbilt University |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Body Mass Index Z-score | Baseline, 16 Weeks | ||
Secondary | Changes in Additional Body Composition Parameters (Absolute Change in Weight) | Baseline, 16 Weeks | ||
Secondary | Changes in Additional Body Composition Parameters (Relative Change in Weight) | Baseline, 16 Weeks | ||
Secondary | Changes in Additional Body Composition Parameters (Absolute BMI) | Baseline, 16 Weeks | ||
Secondary | Changes in Additional Body Composition Parameters (Abdominal Circumference) | Baseline, 16 Weeks | ||
Secondary | Changes in Additional Body Composition Parameters (Hip Circumference) | Baseline, 16 Weeks | ||
Secondary | Changes in Fasting Metabolic Parameters (Total Cholesterol) | Baseline, 16 Weeks | ||
Secondary | Changes in Fasting Metabolic Parameters (LDL) | Baseline, 16 Weeks | ||
Secondary | Changes in Fasting Metabolic Parameters (HDL) | Baseline, 16 Weeks | ||
Secondary | Changes in Fasting Metabolic Parameters (Triglycerides) | Baseline, 16 Weeks | ||
Secondary | Changes in Fasting Metabolic Parameters (Glucose) | Baseline, 16 Weeks | ||
Secondary | Changes in Fasting Metabolic Parameters (Insulin) | Baseline, 16 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Completed |
NCT03097237 -
High Fiber Rye Foods for Weight and Body Fat Reduction
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 |